272 related articles for article (PubMed ID: 12505689)
1. The quest for a vascular endothelial cannabinoid receptor.
Kunos G; Bátkai S; Offertáler L; Mo F; Liu J; Karcher J; Harvey-White J
Chem Phys Lipids; 2002 Dec; 121(1-2):45-56. PubMed ID: 12505689
[TBL] [Abstract][Full Text] [Related]
2. Mesenteric vasodilation mediated by endothelial anandamide receptors.
Wagner JA; Varga K; Járai Z; Kunos G
Hypertension; 1999 Jan; 33(1 Pt 2):429-34. PubMed ID: 9931142
[TBL] [Abstract][Full Text] [Related]
3. Endocannabinoids and vascular function.
Hillard CJ
J Pharmacol Exp Ther; 2000 Jul; 294(1):27-32. PubMed ID: 10871291
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.
Járai Z; Wagner JA; Varga K; Lake KD; Compton DR; Martin BR; Zimmer AM; Bonner TI; Buckley NE; Mezey E; Razdan RK; Zimmer A; Kunos G
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14136-41. PubMed ID: 10570211
[TBL] [Abstract][Full Text] [Related]
5. Endocannabinoids: a new class of vasoactive substances.
Randall MD; Kendall DA
Trends Pharmacol Sci; 1998 Feb; 19(2):55-8. PubMed ID: 9550942
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular effects of cannabinoids.
Randall MD; Harris D; Kendall DA; Ralevic V
Pharmacol Ther; 2002 Aug; 95(2):191-202. PubMed ID: 12182966
[TBL] [Abstract][Full Text] [Related]
7. Cell signaling by endocannabinoids and their congeners: questions of selectivity and other challenges.
Schmid HH; Schmid PC; Berdyshev EV
Chem Phys Lipids; 2002 Dec; 121(1-2):111-34. PubMed ID: 12505695
[TBL] [Abstract][Full Text] [Related]
8. Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators.
Di Marzo V
Life Sci; 1999; 65(6-7):645-55. PubMed ID: 10462065
[TBL] [Abstract][Full Text] [Related]
9. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.
Golech SA; McCarron RM; Chen Y; Bembry J; Lenz F; Mechoulam R; Shohami E; Spatz M
Brain Res Mol Brain Res; 2004 Dec; 132(1):87-92. PubMed ID: 15548432
[TBL] [Abstract][Full Text] [Related]
10. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
Gonsiorek W; Lunn C; Fan X; Narula S; Lundell D; Hipkin RW
Mol Pharmacol; 2000 May; 57(5):1045-50. PubMed ID: 10779390
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular effects of endocannabinoids--the plot thickens.
Kunos G; Járai Z; Varga K; Liu J; Wang L; Wagner JA
Prostaglandins Other Lipid Mediat; 2000 Apr; 61(1-2):71-84. PubMed ID: 10785543
[TBL] [Abstract][Full Text] [Related]
12. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol.
Hillard CJ
Prostaglandins Other Lipid Mediat; 2000 Apr; 61(1-2):3-18. PubMed ID: 10785538
[TBL] [Abstract][Full Text] [Related]
13. A new endothelial target for cannabinoids.
Randall MD
Mol Pharmacol; 2003 Mar; 63(3):469-70. PubMed ID: 12606752
[No Abstract] [Full Text] [Related]
14. Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase.
Reggio PH; Traore H
Chem Phys Lipids; 2000 Nov; 108(1-2):15-35. PubMed ID: 11106780
[TBL] [Abstract][Full Text] [Related]
15. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
Melck D; De Petrocellis L; Orlando P; Bisogno T; Laezza C; Bifulco M; Di Marzo V
Endocrinology; 2000 Jan; 141(1):118-26. PubMed ID: 10614630
[TBL] [Abstract][Full Text] [Related]
16. 2-Arachidonoylglycerol and anandamide oppositely modulate norepinephrine release from the rat heart sympathetic nerves.
Kurihara J; Nishigaki M; Suzuki S; Okubo Y; Takata Y; Nakane S; Sugiura T; Waku K; Kato H
Jpn J Pharmacol; 2001 Sep; 87(1):93-6. PubMed ID: 11676206
[TBL] [Abstract][Full Text] [Related]
17. Endocannabinoids as cardiovascular modulators.
Kunos G; Járai Z; Bátkai S; Goparaju SK; Ishac EJ; Liu J; Wang L; Wagner JA
Chem Phys Lipids; 2000 Nov; 108(1-2):159-68. PubMed ID: 11106789
[TBL] [Abstract][Full Text] [Related]
18. 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance.
Di Marzo V
Biochim Biophys Acta; 1998 Jun; 1392(2-3):153-75. PubMed ID: 9630590
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta.
Herradón E; Martín MI; López-Miranda V
Br J Pharmacol; 2007 Nov; 152(5):699-708. PubMed ID: 17704831
[TBL] [Abstract][Full Text] [Related]
20. Endocannabinoids.
Mechoulam R; Fride E; Di Marzo V
Eur J Pharmacol; 1998 Oct; 359(1):1-18. PubMed ID: 9831287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
